Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study
- 602 Downloads
The present study evaluated the feasibility and effectiveness of myeloablative high-dose chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors (CNS-GCTs). Eleven patients with non-germinomatous germ cell tumors and nine patients with germinomas were enrolled. Patients received between two and eight cycles of conventional chemotherapy prior to HDCT/autoSCT with or without radiotherapy. Overall, 16 patients proceeded to the first HDCT/autoSCT, and nine proceeded to the second HDCT/autoSCT. CTE (carboplatin–thiotepa–etoposide) and cyclophosphamide–melphalan (CM) regimens were used for the first and second HDCT, respectively. Toxicities during HDCT/autoSCT were acceptable, and there were no treatment-related deaths. Twelve patients experienced relapse or progression; however, four patients with germinomas remain alive after subsequent RT. Therefore, a total of 12 patients (four NGGCTs and eight germinomas) remain alive with a median follow-up of 47 months (range 22–90) after relapse or progression. The probability of 3-year overall survival was 59.1 ± 11.2 % (36.4 ± 14.5 % for NGGCTs vs. 88.9 ± 10.5 % for germinomas, P = 0.028). RT, particularly craniospinal RT, was associated with a better tumor response prior to HDCT/autoSCT and a better final outcome. In conclusion, HDCT/autoSCT was feasible, and survival rates were encouraging. Further study with a larger cohort of patients is needed to elucidate the role of HDCT/autoSCT in the treatment of relapsed or progressed CNS-GCTs.
KeywordsCentral nervous system germ cell tumor High-dose chemotherapy Autologous stem cell transplantation
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (No. 0520300).
Conflict of interest
We declare that there is no competing financial interest in relation to this work.
- 5.Ogawa K, Toita T, Nakamura K, Uno T, Onishi H, Itami J, Shikama N, Saeki N, Yoshii Y, Murayama S (2003) Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors: a multi-institutional retrospective analysis of 41 patients. Cancer 98:369–376PubMedCrossRefGoogle Scholar
- 6.Kretschmar C, Kleinberg L, Greenberg M, Burger P, Holmes E, Wharam M (2007) Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 48:285–291PubMedCrossRefGoogle Scholar
- 10.Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2007) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J Clin Oncol 27:1007–1013CrossRefGoogle Scholar
- 12.Sung KW, Yoo KH, Cho EJ, Koo HH, Lim do H, Shin HJ, Ahn SD, Ra YS, Choi ES, Ghim TT (2007) High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 48:408–415PubMedCrossRefGoogle Scholar
- 13.Sung KW, Lim do H, Son MH, Lee SH, Yoo KH, Koo HH, Kim JH, Suh YL, Joung YS, Shin HJ (2013) Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma. Neuro Oncol 15:352–359PubMedCrossRefGoogle Scholar
- 15.Mahoney DH Jr, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H (1996) High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 14:382–388PubMedGoogle Scholar
- 16.Graham ML, Herndon JE 2nd, Casey JR, Chaffee S, Ciocci GH, Krischer JP, Kurtzberg J, Laughlin MJ, Longee DC, Olson JF, Paleologus N, Pennington CN, Friedman HS (1997) High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 15:1814–1823PubMedGoogle Scholar
- 18.Biassoni V, Massimono M, Gandola L, Spreafico E, Seregni M, Terenziani E, Pignoli R, Luksch F, Pallotti M, Casanova C, Meazza G, Cefalo A, Ferrari D, Polastri M, Podda F, Fossati-Bellani (2006) The role of high dose chemotherapy in the treatment of central nervous system germ cell tumours [abstract]. Haematol Rep 2:1Google Scholar
- 21.Calaminus G, Patte C (2002) Experience within the SIOP CNS GCT 96 trial/SFOP studies with HDC/SCR in patients with CNS germ cell tumours and further implications for high risk patients [abstract 54]. Bone Marrow Transpl 30:34Google Scholar
- 22.Frappaz D, Patte C, Peciulyte V, Baranzelli MC, Apapetite C, Kalifa C (2006) High dose vp16-thiotepa (HD VP-TTP) with PBSC rescue in relapsing intra cranial non germinomatous germ cell tumors (ICNGGCT): the SFCE retrospective experience [abstract]. Haematol Rep 2:6Google Scholar
- 23.Patte C, Frappaz D, Peciulyte V, Baranzelli MC, Pichon F, Coze C, Apapetite C, Kalifa C (2006) High dose vp16-thiotepa (HD VP-TTP) with PBSC rescue in relapsing intra cranial germinomas (ICG): the SFCE retrospective experience [abstract]. Haematol Rep 2:12Google Scholar
- 25.Finlay J, Stahl R, Haduong J, Dhall G, Torkildson J, Gardner S, Allen J (2011) Outcome of patients with recurrent central nervous system germ cell tumor: a retrospective study, 2003–2010 [abstract]. Pediatr Blood Cancer 57:727Google Scholar
- 28.Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, Rademaker A, Schaefer C, Evans L, Fouts M, Goldman S (2010) A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. J Neurooncol 97:247–255PubMedCrossRefGoogle Scholar